0 antall prosjekter

GNBIO-Grunnleggende næringsrettet bioteknologi

Development of assays for diagnostics of viral diseases in farmed salmon: New tools for disease control based on host-pathogen interaction

...

Tildelt: kr 1,7 mill.

Prosjektperiode: 2008-2011

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Exploring the T cell receptor genome - the next generation cancer immunotherapeutics

We will generate recombinant T cell receptors (TCRs) that recognize cancer cells. DNA encoding the receptors forms basis for novel drugs for immunotherapy of cancer. Two strategies are followed to select T cells with the desired receptors: 1) T cells that recognize telomerase have been isolated ...

Tildelt: kr 2,3 mill.

Prosjektperiode: 2007-2012

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Targeting of a PKA-AKAP18d-phospholamban signalling complex in the heart as therapy for chronic heart failure

The adrenalin-beta-adrenergic receptor-cAMP-protein kinase A signalling pathway regulates heart rate and contractility. Although changes in cardiac myocyte contractility either cause or are associated with cardiovascular disease, surprisingly few drugs ar e available that modulate the cardiac myo...

Tildelt: kr 2,8 mill.

Prosjektperiode: 2007-2012

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Tumor Targeting Antibodies in Colorectal Cancer

Objective: The main purpose is to identify and characterize novel antibodies recognizing specific antigens on colorectal cancer cells. Interesting candidates will be thoroughly examined for their specificity and their ability to be used as diagnostic and/ or prognostic markers. Their potential as...

Tildelt: kr 2,2 mill.

Prosjektperiode: 2007-2011

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Genetic Engineering of the Plastid Genome for the Efficient Production of Proteins of Biotechnological Importance

The pharmaceutical industry is undergoing remarkable changes with the discovery and introduction of new biotech drugs. However, the production of biotech drugs is both complicated and time-consuming. This is mainly due to production costs using traditiona l cell culture methods. To overcome this ...

Tildelt: kr 1,5 mill.

Prosjektperiode: 2007-2009

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Development of specific PKA-type I and type II anchoring disruptors as drug candidates

The cyclic-AMP-protein kinase A (cAMP-PKA) pathway is one of the most common and versatile signal pathways in eukaryotic cells and is involved in regulation of cellular functions in almost all tissues in mammals. An emerging principle is that function of the cAMP-PKA signal pathway requires subce...

Tildelt: kr 0,77 mill.

Prosjektperiode: 2005-2006

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Commercialisation of novel anti-psoriatic compounds

About 2% of the western world population suffers from psoriasis. Psoriasis is an autoimmune disease characterised by epidermal hyperproliferation and inflammation. The inflammatory process involves several types of cells and signalling compounds in a comp licated cascade. In psoriatic skin, the P...

Tildelt: kr 0,90 mill.

Prosjektperiode: 2005-2006

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Characterization and exploration of microbial enzymes for processing of chitin, chitosan and peptidoglycan

The availability of an increasing number of microbial genomes, including the genome of the highly versatile white-rot basidiomycete Phanerochaete chrysosporium, offers unique possibilities to study and explore enzymes with potential biotechnological appli cations. In the present project, we will ...

Tildelt: kr 5,4 mill.

Prosjektperiode: 2005-2010

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Enzyme evolution and advanced strain engineering in biorprocess development

...

Tildelt: kr 8,2 mill.

Prosjektperiode: 2005-2011

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Molecular and functional studies of the WAVE-like regulatory protein complex in Arabidopsis thaliana

The recent years, much attention has been directed towards the mechanisms that regulate the actin cytoskeleton in eukaryotic organisms. In mammalian cells, the ARP2/3 protein complex and its' regulators, WASP and WAVE, are central activators of actin nucl eation and polymerisation, leading to the...

Tildelt: kr 5,8 mill.

Prosjektperiode: 2005-2011

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Selection and characterization of novel cancer specific antibodies – utilization in diagnostic and therapeutic approaches

Objective: The main purpose is to identify and characterize novel breast cancer specific antibodies. Interesting candidates will be thoroughly characterized for their specificity. Fulfilling the specificity criteria their potential as diagnostic or progno stic markers will be investigated. Finall...

Tildelt: kr 4,0 mill.

Prosjektperiode: 2005-2010

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Development of Reporter Mice Models for Preclinical Screening of Drug

The research group of Professor Rune Blomhoff at the University of Oslo has recently established an in vivo molecular imaging model (e.g. transgenic mice carrying NF-kB, ARE, DR5 or GCS regulated luciferase reporter) aimed at identifying factors affecting relevant gene regulation in vivo in a ph...

Tildelt: kr 3,6 mill.

Prosjektperiode: 2005-2008

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

RNA interference targeting Tissue Factor, a novel principle for cancer therapy.

The principal goal of this project is to explore the use of RNA interference (RNAi) technology in cancer therapy using Tissue Factor (TF) as a target. The project is based upon recent advances in RNAi technology and in our understanding of the role of TF in cancer cell biology. The cloning of T...

Tildelt: kr 2,8 mill.

Prosjektperiode: 2005-2008

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Novel biologically active molecules through a combined application of bioinformatics and genetic engineering

The proposed research project is intended to further develop and test a unique drug discovery platform created at the NTNU/SINTEF (Norway) and the Institute of Biomedical Chemistry (Russia), which is composed of a powerful new bioinformatics tool and a te chnology for gene manipulation of antibio...

Tildelt: kr 5,3 mill.

Prosjektperiode: 2005-2009

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Developmental Genomics of Oikopleura, a marine architect at the invertebrate/vertebrate transition. (OIKOGEN)

...

Tildelt: kr 6,4 mill.

Prosjektperiode: 2002-2006

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Vibrio salmonicida: A model organism for the study of virulence, host specificy and adaptation in fish

...

Tildelt: kr 6,1 mill.

Prosjektperiode: 2002-2007

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Functional and bioinformatical analysis of the evolutionarily conserved chromatin modulation SET-domain proteins

...

Tildelt: kr 6,8 mill.

Prosjektperiode: 2002-2006

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Oppklaring av molekylær mekanisme for proinflammatorisk fosfolipase A2

Inflammasjon er felles symptom for alle kroniske sykdommer så som astma, allergi, leddgikt, diverse hudsykdommer, f.ex. psoriasis, hjerte/kar-sykdom, Crohns sykdom etc. Inflammasjon reguleres av lipidderiverte hormoner, nemlig eicosanoider og lysofosfolip id (IPL)-derivater som alle syntetiseres ...

Tildelt: kr 4,9 mill.

Prosjektperiode: 2002-2008

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

Molecular mechanisms of natural transformation: impact on virulence and genome variability in the pneumococcus and the pathogenic Neisseria

...

Tildelt: kr 4,2 mill.

Prosjektperiode: 2002-2006

Sted: Ukjent Fylke

GNBIO-Grunnleggende næringsrettet bioteknologi

New antibiotics via rational genetic engineering of the nystatin biosynthetic genes

...

Tildelt: kr 7,2 mill.

Prosjektperiode: 2002-2006

Sted: Ukjent Fylke